Can we think of a TAT, that is a "tailored antiplatelet therapy"?
Luigi TritapepeClaudio A Ajmone CatPublished in: Journal of cardiac surgery (2021)
What can be seen from the case report by Verzelloni et al. has a double value, beyond the case itself. First of all, the use of platelet aggregation assessment tests, such as TEG-PM, allows clinicians to verify the exact timing between the suspension of thienopyridines and the possibility of surgery without further temporal delays and is also able to favor the evolution of ischemic problems or hemodynamic instability not easily treatable. It, therefore, allows clinicians to optimize the bleeding/thrombosis matching. Second, the use of point of care methodologies for the evaluation of platelet aggregation allows us to evaluate the adequacy of the antiaggregation, facilitating, where resistance or percentages of antiaggregation are lower than expected, modification of the therapeutic regimen.
Keyphrases
- antiplatelet therapy
- case report
- percutaneous coronary intervention
- acute coronary syndrome
- coronary artery bypass
- palliative care
- minimally invasive
- mental health
- pulmonary embolism
- particulate matter
- atrial fibrillation
- air pollution
- heavy metals
- ischemia reperfusion injury
- density functional theory
- coronary artery disease
- polycyclic aromatic hydrocarbons
- oxidative stress
- smoking cessation
- surgical site infection
- cerebral ischemia
- water soluble
- subarachnoid hemorrhage